HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E5768 Indolelactic acid Indolelactic acid (Indole-3-lactic acid), a metabolite of tryptophan (Trp), plays a role in immune cell differentiation and cytokine production by activating aryl hydrocarbon receptors (AhR). This regulation supports immune responses and aids in anti-inflammatory and anti-allergic activities. It also plays an important role in the balance of Th17/Treg cells by reprogramming CD4+ Th cells into CD4+CD8+ Treg cells and inhibiting the polarization of Th17 cells. Nov 29 2024
A2167 Anti-mouse CD3-InVivo Anti-mouse CD3-InVivo reacts with mouse CD3, a transmembrane cell-surface protein that belongs to the immunoglobulin superfamily.CD3 is expressed on T lymphocytes, NK-T cells, and to varying degrees on developing thymocytes. Nov 29 2024
E1814 Resigratinib Resigratinib (KIN-3248) is a potent, kinome selective, irreversible, orally bioavailable, small-molecule inhibitor of pan-FGFR. It exhibits dose-dependent tumor inhibition in FGFR driven cholangiocarcinoma, gastric, and bladder cancer xenograft models. Nov 27 2024
E4792 Atorvastatin calcium hydrate Atorvastatin calcium hydrate (Totalip) is a potent inhibitor of the HMG-CoA reductase . It is used as a potent hypolipidemic agent to reduce the elevated total-cholesterol, low-density lipoprotein (LDL), apolipoprotein B (apo B), and triglyceride (TG) levels, and to increase the high-density lipoprotein cholesterol (HDL-C) level in patients with primary hypercholesterolemia and mixed dyslipidemia. Nov 27 2024
E4994 JNJ-75276617 JNJ-75276617 (Bleximenib, Menin-MLL inhibitor 24) is an orally bioavailable, potent inhibitor of menin targeting the menin-KMT2A selective protein-protein interaction. It also acts as an inhibitor of menin-mixed-lineage leukemia 1 (menin-MLL). JNJ-75276617 displays highly potent antiproliferative activity across several acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) cell lines and patient samples. Nov 25 2024
E4800 BML-284 BML-284 (Wnt Agonist) is a potent and cell-permeable activator of Wnt signaling that induces TCF-dependent transcriptional activity with an EC50 value of 0.7 µM. BML-284 also acts as an agonist of β-catenin that effectively activates direct Wnt-β-catenin signaling to induce adipocyte dedifferentiation while circumventing the apoptotic effect in the hypertonic treatment. Nov 25 2024
E4719 XYL-1 XYL-1 is a highly potent inhibitor of PARP7 with and IC50 of 0.6 nM. It could enhance the type-Ⅰinterferon signaling in vitro, and can be a potential candidate for developing cancer immunotherapy agents. Nov 25 2024
E4637 PK 11195 PK 11195 (RP 52028) is a translocator protein (TSPO) ligand, a potent and selective antagonist of peripheral benzodiazepine receptorwith high affinity Ki of 3.1 nM in cerebellum and 4.1 nM in spinal cord. It is also an antagonist of human constitutive androstane receptor (hCAR), and human pregnane X receptor (PXR). It displaces [3H] RO5-4864 from its binding sites across organs and also targets Leishmania in chemotherapy. Nov 25 2024
E4793 Bucladesine calcium Bucladesine calcium (Dibutyryl-cAMP Calcium Salt, DBcAMP calcium salt) is a cell-permeable analog of cyclic AMP. It serves as a potent activator of protein kinase A (PKA) and mimics the effects of endogenous cAMP. It also inhibits phosphodiesterase (PDE) activity, with the potential to treat congestive heart failure, wound healing, and inflammation. Nov 25 2024
E4681 PF-07799933 PF-07799933 (Claturafenib, ARRY-440) is a brain-penetrant, selective, pan-mutant inhibitor of BRAF. It exhibits broad inhibition of pERK levels in HT29 cells with an IC50 value of 1.6 nM. PF-07799933 treatment displays antitumor activity against BRAFV600- and non-V600-mutant cancers preclinically and in treatment-refractory patients. Nov 24 2024
E6015 Heparin (Lithium salt) Heparin Lithium salt is an anticoagulant that binds reversibly to antithrombin III (ATIII). Heparin Lithium salt is used as an anticoagulant for laboratory studies and in direct membrane-feeding assays. Nov 24 2024
E6009 Esomeprazole Esomeprazole ((S)-Omeprazole, (-)-Omeprazole) is a potent inhibitor of proton pump. It decreases acid production by inhibiting the H+, K+-ATPase enzyme in gastric parietal cells. Esomeprazole displays pharmacokinetic properties that make it more effective than omeprazole and has the potential for use in research of symptomatic gastroesophageal reflux disease. Nov 24 2024
E6013 Sivelestat sodium Sivelestat sodium (ONO-5046, Sodium sivelestat, LY544349 sodium) is a potent, specific, and intravenously active inhibitor of neutrophil elastase with an IC50 value of 44 nm. It is a useful agent for studying the roles of neutrophil elastase in animal disease models such as emphysema, adult respiratory distress syndrome, septic shock and disseminated intravascular coagulation in COVID-19. Nov 21 2024
E1628 BMS-911172 BMS-911172 is a brain penetrant, selective inhibitor of adaptor protein 2-associated kinase 1 (AAK1) with an IC50 value of 12 nM. BMS-911172 inhibits μ2 phosphorylation and has potential as a therapeutic agent in neuropathic pain research. Nov 21 2024
E4657 PFI-6 PFI-6 is a selective MLLT1/3 probe that targets the YEATS domain of MLLT1 (ENL/YEATS1) and MLLT3 (AF9/YEATS3) with IC50 values of 140 nM and 160 nM for MLLT1 and MLLT3, respectively. PFI-6 demonstrates increased affinity and selectivity for MLLT1/3 than other human YEATS domain proteins (YEATS2/4). Nov 20 2024
E4977 Zileuton sodium Zileuton sodium (A 64077 sodium) is a potent, selective, and specific inhibitor of 5-lipoxygenase, exhibiting inflammatory activities. Zileuton sodium prevents polyp formation efficiently by reducing tumor-associated and systemic inflammation in in vivo models. Zileuton sodium also acts as a potential chemo-preventive agent in patients that are at high risk of developing colon cancer. Nov 20 2024
E1563 GNE-7883 GNE-7883 is a potent and allosteric small-molecule inhibitor of pan-TEAD, that allosterically blocks the interactions between YAP/TAZ and all human TEAD paralogs through binding to the TEAD lipid pocket. It effectively reduces chromatin accessibility at TEAD motifs, suppresses cell proliferation in a variety of cell line models and achieves strong antitumor efficacy in vivo. Furthermore, it effectively overcomes KRAS G12C inhibitor resistance. Nov 17 2024
E1856 ARS-1323 ARS-1323 is the racemic mixture, containing ARS-1620, and a potent inhibitor of mutant KRAS G12C. It can be used in research for biochemical binding screens as companion imaging drugs (CID) for KRAS G12C. Nov 17 2024
E4791 Adezmapimod hydrochloride Adezmapimod hydrochloride (RWJ 64809 hydrochloride, SB 203580 hydrochloride) is an inhibitor of the MAPK family member termed as stress-activated protein kinase 2a(SAPK2a; also known as p38). It exhibits IC50 of SAPK2a/p38 and SAPK2b/p38β2 with IC50 values of 50 nM and 500 nM respectively and can be used in research of chronic inflammatory diseases, such as rheumatoid arthritis. Nov 17 2024
E4778 BODIPY 493/503 BODIPY 493/503 (Pyrromethene 546, BDP 493/503 lipid stain) is a fluorescent neutral lipophilic dye. It is used to facilitate quantification of neutral lipid content, a lipid droplet–associated protein by flow cytometry and observation of lipid droplets(LDs) by microscopy. Nov 17 2024